Detalles de la búsqueda
1.
Pneumococcal Vaccination Strategies in 50-Year-Olds to Decrease Racial Disparities: A US Societal Perspective Cost-Effectiveness Analysis.
Value Health
; 27(6): 721-729, 2024 Jun.
Artículo
Inglés
| MEDLINE | ID: mdl-38462225
2.
Cost-Effectiveness of Pneumococcal Vaccination and Uptake Improvement Programs in Underserved and General Population Adults Aged < 65 Years.
J Community Health
; 45(1): 111-120, 2020 02.
Artículo
Inglés
| MEDLINE | ID: mdl-31401746
3.
Cost-effectiveness of increasing vaccination in high-risk adults aged 18-64 Years: a model-based decision analysis.
BMC Infect Dis
; 18(1): 52, 2018 01 25.
Artículo
Inglés
| MEDLINE | ID: mdl-29370768
4.
Societal Cost of Racial Pneumococcal Disease Disparities in US Adults Aged 50 Years or Older.
Appl Health Econ Health Policy
; 22(1): 61-71, 2024 Jan.
Artículo
Inglés
| MEDLINE | ID: mdl-37966698
5.
Changes in the cost-effectiveness of pneumococcal vaccination and of programs to increase its uptake in U.S. older adults.
J Am Geriatr Soc
; 2024 Jun 01.
Artículo
Inglés
| MEDLINE | ID: mdl-38822745
6.
Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older.
Vaccine
; 42(12): 3024-3032, 2024 Apr 30.
Artículo
Inglés
| MEDLINE | ID: mdl-38580515
7.
Only adding stationary storage to vaccine supply chains may create and worsen transport bottlenecks.
J Public Health Manag Pract
; 19 Suppl 2: S65-7, 2013.
Artículo
Inglés
| MEDLINE | ID: mdl-23903398
8.
Cost-effectiveness of an in-development adult-formulated pneumococcal vaccine in older US adults.
Vaccine
; 41(30): 4431-4437, 2023 07 05.
Artículo
Inglés
| MEDLINE | ID: mdl-37316409
9.
Impact of introducing the pneumococcal and rotavirus vaccines into the routine immunization program in Niger.
Am J Public Health
; 102(2): 269-76, 2012 Feb.
Artículo
Inglés
| MEDLINE | ID: mdl-21940923
10.
Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine.
JAMA
; 307(8): 804-12, 2012 Feb 22.
Artículo
Inglés
| MEDLINE | ID: mdl-22357831
11.
Cost-effectiveness of revised US pneumococcal vaccination recommendations in underserved minority adults < 65-years-old.
Vaccine
; 40(50): 7312-7320, 2022 11 28.
Artículo
Inglés
| MEDLINE | ID: mdl-36336526
12.
Cost-Effectiveness of Newly Recommended Pneumococcal Vaccination Strategies in Older Underserved Minority Adults in the USA.
Infect Dis Ther
; 11(4): 1683-1693, 2022 Aug.
Artículo
Inglés
| MEDLINE | ID: mdl-35831685
13.
Impact of changing the measles vaccine vial size on Niger's vaccine supply chain: a computational model.
BMC Public Health
; 11: 425, 2011 Jun 02.
Artículo
Inglés
| MEDLINE | ID: mdl-21635774
14.
Should older adult pneumococcal vaccination recommendations change due to decreased vaccination in children during the pandemic? A cost-effectiveness analysis.
Vaccine
; 39(31): 4278-4282, 2021 07 13.
Artículo
Inglés
| MEDLINE | ID: mdl-34167834
15.
Higher-Valency Pneumococcal Conjugate Vaccines: An Exploratory Cost-Effectiveness Analysis in U.S. Seniors.
Am J Prev Med
; 61(1): 28-36, 2021 07.
Artículo
Inglés
| MEDLINE | ID: mdl-34148625
16.
Is further research on adult pneumococcal vaccine uptake improvement programs worthwhile? Α value of information analysis.
Vaccine
; 39(27): 3608-3613, 2021 06 16.
Artículo
Inglés
| MEDLINE | ID: mdl-34045104
17.
Cost-Effectiveness of Pneumococcal Vaccination Policies and Uptake Programs in US Older Populations.
J Am Geriatr Soc
; 68(6): 1271-1278, 2020 06.
Artículo
Inglés
| MEDLINE | ID: mdl-32086950
18.
Pneumococcal Vaccination in Adults Aged ≥65 Years: Cost-Effectiveness and Health Impact in U.S. Populations.
Am J Prev Med
; 58(4): 487-495, 2020 04.
Artículo
Inglés
| MEDLINE | ID: mdl-32001052
19.
Cost-effectiveness of adult pneumococcal vaccination policies in underserved minorities aged 50-64â¯years compared to the US general population.
Vaccine
; 37(14): 2026-2033, 2019 03 28.
Artículo
Inglés
| MEDLINE | ID: mdl-30846259
20.
An intervention to improve pneumococcal vaccination uptake in high risk 50-64 year olds vs. expanded age-based recommendations: an exploratory cost-effectiveness analysis.
Hum Vaccin Immunother
; 15(4): 863-872, 2019.
Artículo
Inglés
| MEDLINE | ID: mdl-30633706